Dr Reddy’s Laboratories is currently trading at Rs 1570.00, up by 4.10 points or 0.26% from its previous closing of Rs 1565.90 on the BSE.
The scrip opened at Rs. 1551.00 and has touched a high and low of Rs 1582.00 and Rs 1551.00 respectively. So far 4591 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs 1728.90 on 06-Jan-2011 and a 52 week low of Rs 1387.00 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs 1619.00 and Rs 1551.00 respectively. The current market cap of the company is Rs 26567.55 crore.
The promoters holding in the company stood at 25.61% while Institutions and Non-Institutions held 40.74% and 15.99% respectively.
Dr Reddy’s Laboratories has unveiled Supamove cream used for treating pain and inflammation in India. The cream helps in reducing pain and inflammation in patients with joint pain, arthritis, bursitis, tendinitis and lower back pain. In addition, the product has been in-licensed from Cymbiotics Inc. USA and will be available in a 30 gm tube.
The company has also launched another product, Venusia Soft lotion in 75 ml pack, used for providing relief from dry, itchy skin also in-licensed from Cymbiotics Inc.
Dr Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: